Kempharm Inc., of Coralville, Iowa, priced $75 million aggregate principal amount of 5.5 percent senior convertible notes due 2021 in a private placement to qualified institutional buyers, granting the initial purchasers of the notes a 30-day option to purchase up to an additional $11.25 million more to cover overallotments. The sale of the notes is expected to close next Tuesday. Cowen and Co. is acting as lead book-running manager, RBC Capital Markets is book-running manager and Canaccord Genuity and Oppenheimer and Co. are serving as co-managers.